The Food and Drug Administration (FDA) can maintain its high bar for safety and efficacy, and also cut the waste and unnecessary delays in the regulatory process.

Food and Drug Administration Commissioner Marty Makary said his agency may fast-track new drugs from pharmaceutical companies that “equalize” the cost of their medicines between the US and other ...

By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often ...

The U.S. Food and Drug Administration is calling for increased attention to product recall communications from industry ...

FDA Commissioner Dr. Marty Makary joins ‘Fox & Friends’ co-host Steve Doocy for a morning walk to discuss the agency’s focus on food safety and the Make America Healthy Again movement.

The U.S. Food and Drug Administration may reportedly fast-track new drugs from pharmaceutical companies that “equalize” the ...

The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...

The FDA published a database of letters sent to drugmakers during the review process of medications that provide information on the agency's initial feedback or requirements for more data. These ...

FDA head Marty Makary said the agency may fast-track drugs from companies that “equalize” the cost of medicines between the U ...

It is unclear how the Trump administration will consider affordability when reviewing a drug, as prices are usually ...

FDA Commissioner Marty Makary suggests his agency may expedite drug reviews for manufacturers reducing U.S. prices to global ...